MEDICAL BIOTECH FIRM GOES BUST
miss shelley | 07.07.2006 23:59 | Bio-technology | Ecology | Health | World
+ VICTIMS' AGONY AS DRUGS FIRM GOES BUST
The Daily Mail reports that the victims of the 'Elephant Man' drug trials have
been left in even more misery after the company that made the drug went bust.
However, the article omits to mention that this drug - TGN1412 - with its
disastrous and "unexpected biological effect" was genetically engineered.
The Daily Mail reports that the victims of the 'Elephant Man' drug trials have
been left in even more misery after the company that made the drug went bust.
However, the article omits to mention that this drug - TGN1412 - with its
disastrous and "unexpected biological effect" was genetically engineered.
MEDICAL BIOTECH
------------------------------------------------------------
Six men suffered multiple organ failure when they were the first humans to try
the drugs in London in March - with the head of one victim swelling to three
times its normal size.
They are all hoping for a huge compensation payout to help them through the rest
of their lives, but that hope was hit by the news that the German pharmaceutical
firm TeGenero had filed for insolvency.
A spokesman for TeGenero said the "unforeseeable adverse reactions" caused by
the drug, known as TGN1412, "have made it impossible to attract the investment
necessary for the company to continue operations".
It had already emerged that the firm involved had just GBP2million insurance.
The men were paid just GBP2,000 for taking part in the trials.
http://www.gmwatch.org/archive2.asp?arcid=6716
------------------------------------------------------------
Six men suffered multiple organ failure when they were the first humans to try
the drugs in London in March - with the head of one victim swelling to three
times its normal size.
They are all hoping for a huge compensation payout to help them through the rest
of their lives, but that hope was hit by the news that the German pharmaceutical
firm TeGenero had filed for insolvency.
A spokesman for TeGenero said the "unforeseeable adverse reactions" caused by
the drug, known as TGN1412, "have made it impossible to attract the investment
necessary for the company to continue operations".
It had already emerged that the firm involved had just GBP2million insurance.
The men were paid just GBP2,000 for taking part in the trials.
http://www.gmwatch.org/archive2.asp?arcid=6716
miss shelley
Comments
Display the following comment